Overview

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

Status:
Recruiting
Trial end date:
2023-02-10
Target enrollment:
0
Participant gender:
All
Summary
This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
LY3298176
Tirzepatide
Criteria
Inclusion Criteria:

- Have a BMI ≥28 kilogram/square meter (kg/m²), or ≥24 kg/m² and previous diagnosis with
at least one of the following comorbidities: hypertension, dyslipidemia, obstructive
sleep apnea, cardiovascular disease

- Have a history of at least one self-reported unsuccessful dietary effort to lose body
weight

Exclusion Criteria:

- Have Diabetes Mellitus

- Have a self-reported change in body weight >5 kg within 3 months prior to screening

- Have obesity induced by other endocrinological disorders

- Have had a history of chronic or acute pancreatitis

- Have a history of significant active or unstable Major Depressive Disorder (MDD) or
other severe psychiatric disorder within the last 2 years

- Have any lifetime history of a suicide attempt

- Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple
endocrine neoplasia syndrome type 2 (MEN-2)